Blog

New drug from Erasca in combination with cetuximab – Chordoma Foundation

Photo taken from Chordoma Foundation/X

Jul 14, 2024, 07:59

New drug from Erasca in combination with cetuximab – Chordoma Foundation

Chordoma Foundation shared a post on X:

“Promising results have emerged from a Phase 1 clinical trial testing a new drug from Erasca called ERAS-601 alone and in combination with cetuximab: Nearly all of the 13 chordoma patients enrolled had some tumor shrinkage.”

Additional information
Source: Chordoma Foundation/X

cancer cetuximab Chordoma Chordoma Foundation ERAS-601 Erasca OncoDaily Oncology tumor shrinkage

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

Special Coverage

ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023

Facebook

RSS Feed

Youtube

Dialogues

Jan 19, 2025, 08:24

Vicki Durston: A steady increase in early-onset breast cancer among young women is drawing global attention

Blog

Jan 19, 2025, 08:21

Michael Sapienza: Amgen’s targeted therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer

Blog

Jan 19, 2025, 08:12

Daneen Sekoni: I'll be participating in the 2025 Cervical Cancer Survivor Summit

Blog

Jan 19, 2025, 08:12

SWOG Cancer Research Network study S2207 is enrolling patients with relapsed, refractory large B-cell lymphoma

Blog

Jan 19, 2025, 08:03

Targetable mutations and tumor microenvironment in urachal cancer

Career

Jan 19, 2025, 07:59

OncoInfluencers to Follow on Social Media: Kara Magsanoc-Alikpala

Science

Jan 19, 2025, 07:56

Piet Ost: Does SBRT for oligorecurrent prostate cancer improve OS as compared to SOC?

Science

Jan 19, 2025, 07:52

Paolo Tarantino: What’s distinct about Breast cancers with ERBB2?

Science

Jan 19, 2025, 07:45

Cristiane Bergerot: Mindfulness via smartphone

Science

Jan 19, 2025, 07:42

Xiuning Le: The number of newly diagnosed female lung cancer cases has surpassed that of males

Insight

Jan 19, 2025, 07:37

Stephanie Graff: Excited to have another therapeutic option to treat advanced HR+ breast cancer

Dialogues

Jan 19, 2025, 07:33

The Experience of Colorectal Cancer Screening in Kazakhstan